Doxorubicin liposomal - Taiwan Liposome Company

Drug Profile

Doxorubicin liposomal - Taiwan Liposome Company

Alternative Names: Lipo-Dox; TLC 177

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiwan Liposome Company
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Kaposi's sarcoma; Ovarian cancer

Most Recent Events

  • 19 May 2017 Preregistration for Breast cancer in European Union (IV)
  • 19 May 2017 Preregistration for Ovarian cancer in European Union (IV)
  • 29 Sep 2016 TLC regains the distribution right for doxorubicin liposomal from Teva for USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top